Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6QF9

Structure of an anti-Mcl1 scFv

Summary for 6QF9
Entry DOI10.2210/pdb6qf9/pdb
Related6qb3 6qb9 6qf6
DescriptorscFv (2 entities in total)
Functional Keywordsmcl1, scfv, apoptosis
Biological sourceHomo sapiens
Total number of polymer chains2
Total formula weight52857.92
Authors
Luptak, J. (deposition date: 2019-01-09, release date: 2019-11-06, Last modification date: 2024-11-06)
Primary citationLuptak, J.,Bista, M.,Fisher, D.,Flavell, L.,Gao, N.,Wickson, K.,Kazmirski, S.L.,Howard, T.,Rawlins, P.B.,Hargreaves, D.
Antibody fragments structurally enable a drug-discovery campaign on the cancer target Mcl-1.
Acta Crystallogr D Struct Biol, 75:1003-1014, 2019
Cited by
PubMed Abstract: Apoptosis is a crucial process by which multicellular organisms control tissue growth, removal and inflammation. Disruption of the normal apoptotic function is often observed in cancer, where cell death is avoided by the overexpression of anti-apoptotic proteins of the Bcl-2 (B-cell lymphoma 2) family, including Mcl-1 (myeloid cell leukaemia 1). This makes Mcl-1 a potential target for drug therapy, through which normal apoptosis may be restored by inhibiting the protective function of Mcl-1. Here, the discovery and biophysical properties of an anti-Mcl-1 antibody fragment are described and the utility of both the scFv and Fab are demonstrated in generating an Mcl-1 crystal system amenable to iterative structure-guided drug design.
PubMed: 31692474
DOI: 10.1107/S2059798319014116
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.43 Å)
Structure validation

236620

PDB entries from 2025-05-28

PDB statisticsPDBj update infoContact PDBjnumon